Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$281,890 | -$341,415 | -$320,827 | $27,733 |
| Dep. & Amort. | $48,913 | $49,001 | $48,253 | $110,650 |
| Deferred Tax | $0 | $0 | $0 | $1,369 |
| Stock-Based Comp. | $18,643 | $15,241 | $22,901 | $1,775 |
| Change in WC | -$29,067 | -$7,129 | -$22,256 | -$317,310 |
| Other Non-Cash | -$1,798 | $8,202 | -$13,777 | $452,799 |
| Operating Cash Flow | -$245,199 | -$276,100 | -$285,706 | $277,016 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$8,444 | -$22,319 | -$42,255 | -$219,450 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | -$63,395 | -$378,376 | $0 |
| Inv. Sales/Matur. | $61,376 | $300,488 | $137,645 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $185,482 |
| Investing Cash Flow | $52,932 | $214,774 | -$282,986 | -$33,968 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $199,821 | $10,567 | -$962 | $0 |
| Stock Issued | $0 | $0 | $0 | $163 |
| Stock Repurch. | $0 | $0 | $0 | -$7,946 |
| Dividends Paid | $0 | $0 | $0 | -$17,706 |
| Other Fin. Act. | $471 | -$435 | $11,407 | -$232,176 |
| Financing Cash Flow | $200,292 | $10,132 | $10,445 | -$249,882 |
| Forex Effect | -$4 | $62 | $2 | $97 |
| Net Chg. in Cash | $8,021 | -$51,132 | -$558,245 | -$6,737 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $60,007 | $111,139 | $669,384 | $73,239 |
| End Cash | $68,028 | $60,007 | $111,139 | $66,502 |
| Free Cash Flow | -$253,643 | -$298,419 | -$327,961 | $57,566 |